Novo CEO Doustdar 'Very Optimistic' About CagriSema

Novo Nordisk A/S Chief Executive Officer Mike Doustdar discusses the possible launch of a new obesity drug called CagriSema. "We are hopeful that we will be able to get the timely approval from the FDA at the end of this year and launch it at the beginning of next year," Doustdar says. He speaks on Bloomberg Television after the company boosted its forecast for the year once again, sparking optimism after the new Wegovy pill and the older shot Ozempic helped buoy earnings.